Monlunabant
A Research Study Investigating Safety and Concentration in the Blood After One Dose Tablet of the New Medicine Monlunabant in Healthy Weight Japanese and Caucasian Men
Inversago Pharma · Phase 1 · Completed · Enrollment 73
Participants reaching threshold, %
Source: Cited trial source. The denominator is the source figure, when it states one.
No selected arm reports a responder percent.
Show as table
| Arm | ≥5% | ≥10% | ≥15% | ≥20% |
|---|---|---|---|---|
| Monlunabant dose 1 | n/r | n/r | n/r | n/r |
| Monlunabant dose 2 | n/r | n/r | n/r | n/r |
| Monlunabant dose 3 | n/r | n/r | n/r | n/r |
| Placebo (monlunabant) | n/r | n/r | n/r | n/r |
Not shown
- Monlunabant dose 1: endpoint not reported
- Monlunabant dose 2: endpoint not reported
- Monlunabant dose 3: endpoint not reported
- Placebo (monlunabant): endpoint not reported